Gentle Touch Hospice Care, Inc 6338 Coldwater Canyon Ave, N Hollywood, CA, 91606 | |
(818) 408-8009 |
News Archive
elsPharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration.
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
A test that examines facial weakness, arm weakness and speech disturbance allows paramedics to quickly and accurately identify stroke, researchers report in today's rapid access issue of Stroke: Journal of the American Heart Association.
Women's perceptions of what is considered normal and desirable female genitalia may be influenced by exposure to modified images, suggests a new study published today (20 December) in BJOG: An International Journal of Obstetrics and Gynaecology.
› Verified 1 days ago
Name | Gentle Touch Hospice Care, Inc |
---|---|
Location | 6338 Coldwater Canyon Ave, N Hollywood, California |
Hospice ID | 751621 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
Accreditation Provider | The Joint Commission (TJC) |
SSA county code | 200 |
News Archive
elsPharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration.
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
A test that examines facial weakness, arm weakness and speech disturbance allows paramedics to quickly and accurately identify stroke, researchers report in today's rapid access issue of Stroke: Journal of the American Heart Association.
Women's perceptions of what is considered normal and desirable female genitalia may be influenced by exposure to modified images, suggests a new study published today (20 December) in BJOG: An International Journal of Obstetrics and Gynaecology.
› Verified 1 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 94.4 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 100.0 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
Patients who got timely treatment for shortness of breath | 96.3 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
elsPharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration.
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
A test that examines facial weakness, arm weakness and speech disturbance allows paramedics to quickly and accurately identify stroke, researchers report in today's rapid access issue of Stroke: Journal of the American Heart Association.
Women's perceptions of what is considered normal and desirable female genitalia may be influenced by exposure to modified images, suggests a new study published today (20 December) in BJOG: An International Journal of Obstetrics and Gynaecology.
› Verified 1 days ago
Home Health Aides | 2 |
Counselors | 1 |
Licensed Practical or Vocational Nurses | 1 |
Medical Social Workers | 1 |
Physicians | 1 |
Registered Nurses | 2 |
Total Employees | 8 |
---|
News Archive
elsPharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration.
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
A test that examines facial weakness, arm weakness and speech disturbance allows paramedics to quickly and accurately identify stroke, researchers report in today's rapid access issue of Stroke: Journal of the American Heart Association.
Women's perceptions of what is considered normal and desirable female genitalia may be influenced by exposure to modified images, suggests a new study published today (20 December) in BJOG: An International Journal of Obstetrics and Gynaecology.
› Verified 1 days ago
Others | 1 |
Total Volunteers | 1 |
---|
News Archive
elsPharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration.
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
A test that examines facial weakness, arm weakness and speech disturbance allows paramedics to quickly and accurately identify stroke, researchers report in today's rapid access issue of Stroke: Journal of the American Heart Association.
Women's perceptions of what is considered normal and desirable female genitalia may be influenced by exposure to modified images, suggests a new study published today (20 December) in BJOG: An International Journal of Obstetrics and Gynaecology.
› Verified 1 days ago
Golden Days Hospice Care, Inc. Location: 10545 Burbank Blvd. #124, N Hollywood, California, 91601 Phone: (818) 408-8009 |
Kmd Hospice, Inc. Location: 11631 Victory Blvd, Ste 201, N Hollywood, California, 91606 Phone: (818) 408-8009 |
California Hospice Care Location: 8001 Laurel Canyon Blvd, Ste 206, N Hollywood, California, 91605 Phone: (818) 408-8009 |
Primary Hospice Care, Inc Location: 7127 Laurel Canyon Blvd., N Hollywood, California, 91605 Phone: (818) 408-8009 |